5 papers in the library · 1,263 citations · publishing 2022-2025
Journal of Eating Disorders May 26, 2025 Julie Trim, Samantha Shao, Nadav Liam Modlin et al. 14 citations
PT may hold promise not only in the treatment of eating disorders but also trauma-related disorders, including PTSD and dissociative amnesia. Potential mechanisms of psilocybin's facilitation of remembering and processing traumatic material is reviewed.
Psychedelics. November 7, 2024 Jessie Kim, Samantha Shao, Julie Trim et al. 2 citations
Anorexia nervosa (AN) is a psychiatric illness with high mortality rates and limited treatment outcomes. Psilocybin treatment (PT) has shown promise for various mental health indications and there is significant interest in exploring its potential for AN; however, studies to date are preliminary. Given the probable surge in psychedelic studies for AN, more information is needed to understand...
FOCUS The Journal of Lifelong Learning in Psychiatry July 1, 2024 Samantha Shao, Tessa Gruen, Alexandra Babakanian et al. 2 citations
Anorexia nervosa (AN) is a deadly illness with no proven treatments to reverse core symptoms and no medications approved by the US Food and Drug Administration. Novel treatments are urgently needed to improve clinical outcomes. In this open-label feasibility study, 10 adult female participants (mean body mass index 19.7 kg m-2; s.d. 3.7) who met Diagnostic and Statistical Manual of Mental...
Nature Medicine July 24, 2023 Samantha Shao, Tessa Gruen, Alexandra Babakanian et al. 150 citations
Abstract Anorexia nervosa (AN) is a deadly illness with no proven treatments to reverse core symptoms and no medications approved by the US Food and Drug Administration. Novel treatments are urgently needed to improve clinical outcomes. In this open-label feasibility study, 10 adult female participants (mean body mass index 19.7 kg m − 2 ; s.d. 3.7) who met Diagnostic and Statistical Manual of...
The New England journal of medicine November 3, 2022 Guy M. Goodwin, Scott T Aaronson, Oscar Alvarez et al. 1,095 citations
Psilocybin is being studied for use in treatment-resistant depression. In this phase 2 double-blind trial, we randomly assigned adults with treatment-resistant depression to receive a single dose of a proprietary, synthetic formulation of psilocybin at a dose of 25 mg, 10 mg, or 1 mg (control), along with psychological support. The primary end point was the change from baseline to week 3 in the...